![Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a](https://www.thelancet.com/cms/attachment/b611936d-5800-49ea-ab56-e932ddaa3aa7/gr1_lrg.jpg)
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a
![Effectiveness of Vaccination and Previous Infection Against Omicron Infection and Severe Outcomes in Children Under 12 Years of Age | medRxiv Effectiveness of Vaccination and Previous Infection Against Omicron Infection and Severe Outcomes in Children Under 12 Years of Age | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2023/01/19/2023.01.18.23284739/F3.large.jpg)
Effectiveness of Vaccination and Previous Infection Against Omicron Infection and Severe Outcomes in Children Under 12 Years of Age | medRxiv
![Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm715152e1_BivalentVaccineEffectiveness_IMAGE_16Dec2022_1200x675.jpg?_=42783)
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR
![Updated COVID-19 booster targets subvariants responsible for 98% of cases today : Oregon Health News Blog Updated COVID-19 booster targets subvariants responsible for 98% of cases today : Oregon Health News Blog](https://i0.wp.com/covidblog.oregon.gov/wp-content/uploads/2022/10/OHA-4320_COVID-19-booster-10.17.22_v1.1.png?resize=489%2C489&ssl=1)
Updated COVID-19 booster targets subvariants responsible for 98% of cases today : Oregon Health News Blog
![Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/683be916-2b6a-4719-b001-feea7e4130e9/gr1.jpg)
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases
NEJM on X: "Figure 1. Effectiveness of Bivalent Boosters According to the Interval since Administration. https://t.co/hIVtIujZoq #Covid19 https://t.co/KBljA6y7NR" / X
![Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - The Lancet Infectious Diseases Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/d32ad5c8-7d62-49cb-bf30-c48c5792fd8b/gr1_lrg.jpg)
Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - The Lancet Infectious Diseases
![Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada | medRxiv Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2023/04/11/2023.04.11.23288403/F1.large.jpg)
Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada | medRxiv
![Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population | Nature Medicine Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-023-02219-5/MediaObjects/41591_2023_2219_Fig1_HTML.png)